ClC Channels and Transporters: Structure, Physiological Functions, and Implications in Human Chloride Channelopathies by Diogo R. Poroca et al.
fphar-08-00151 March 21, 2017 Time: 15:52 # 1
REVIEW
published: 23 March 2017
doi: 10.3389/fphar.2017.00151
Edited by:
Frederic Becq,
University of Poitiers, France
Reviewed by:
Christoph Fahlke,
Forschungszentrum Jülich, Germany
Oscar Moran,
Consiglio Nazionale Delle Ricerche,
Italy
*Correspondence:
Valerie M. Chappe
valerie.chappe@dal.ca
Specialty section:
This article was submitted to
Pharmacology of Ion Channels
and Channelopathies,
a section of the journal
Frontiers in Pharmacology
Received: 22 December 2016
Accepted: 09 March 2017
Published: 23 March 2017
Citation:
Poroca DR, Pelis RM and
Chappe VM (2017) ClC Channels
and Transporters: Structure,
Physiological Functions,
and Implications in Human Chloride
Channelopathies.
Front. Pharmacol. 8:151.
doi: 10.3389/fphar.2017.00151
ClC Channels and Transporters:
Structure, Physiological Functions,
and Implications in Human Chloride
Channelopathies
Diogo R. Poroca1, Ryan M. Pelis2 and Valérie M. Chappe1*
1 Department of Physiology and Biophysics, Dalhousie University, Halifax, NS, Canada, 2 Department of Pharmacology,
Dalhousie University, Halifax, NS, Canada
The discovery of ClC proteins at the beginning of the 1990s was important for the
development of the Cl− transport research field. ClCs form a large family of proteins
that mediate voltage-dependent transport of Cl− ions across cell membranes. They
are expressed in both plasma and intracellular membranes of cells from almost all
living organisms. ClC proteins form transmembrane dimers, in which each monomer
displays independent ion conductance. Eukaryotic members also possess a large
cytoplasmic domain containing two CBS domains, which are involved in transport
modulation. ClC proteins function as either Cl− channels or Cl−/H+ exchangers,
although all ClC proteins share the same basic architecture. ClC channels have
two gating mechanisms: a relatively well-studied fast gating mechanism, and a slow
gating mechanism, which is poorly defined. ClCs are involved in a wide range of
physiological processes, including regulation of resting membrane potential in skeletal
muscle, facilitation of transepithelial Cl− reabsorption in kidneys, and control of pH and
Cl− concentration in intracellular compartments through coupled Cl−/H+ exchange
mechanisms. Several inherited diseases result from C1C gene mutations, including
myotonia congenita, Bartter’s syndrome (types 3 and 4), Dent’s disease, osteopetrosis,
retinal degeneration, and lysosomal storage diseases. This review summarizes general
features, known or suspected, of ClC structure, gating and physiological functions.
We also discuss biophysical properties of mammalian ClCs that are directly involved
in the pathophysiology of several human inherited disorders, or that induce interesting
phenotypes in animal models.
Keywords: ClC channels, myotonia congenita, leukodystrophy, salt loss, deafness, Dent’s disease, osteopetrosis,
channelopathy
Abbreviations: 9-AC, 9-antracene-carboxylic acid; ABC transporters, ATP Binding Cassette transporters; CBS,
cystathionine-β-synthase; cmClC, Cyanidioschyzon merolae ClC protein; CPP, p-chloro-phenoxy-propionic acid; DPC,
N-phenylanthranilic acid; ecClC, Escherichia coli ClC protein; NAD, nicotinamide adenine dinucleotide; NFA, niflumic
acid; PTH, parathyroid hormone; NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid; OADS, 4,4′-octanamidostilbene-
2,2′-disulfonate; PKC, protein kinase C; PTCs, proximal tubule cells; stClC, Salmonella enterica serovar typhimurium ClC
protein; VRAC, volume-regulated anion channel.
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INTRODUCTION
Ion transporters typically use the electrochemical gradient of
one substrate (or another source of energy such as ATP) to
transport another substrate in a well-defined stoichiometry and
direction. This is a relatively slow process limited by the number
of ions/substrate that can bind to the transporter in a given
transport cycle, as well as by the need for conformational changes
to deliver the transported substrate to the opposing side of the
membrane. Conversely, ion channels passively move ions down
electrochemical gradients at a high-rate flux through a pore with
a defined selectivity.
Ion channels commonly exist in four states: closed, open,
inactive, and desensitized, with each state having a different
ion conductance. “Gating” is the term used to describe changes
between the different states. Various factors, including voltage,
ligand binding, second messengers, volume, and temperature
modulate ion channel gating (Kew and Davies, 2010). Because of
their important role in cell function, mutations in ion channel
genes that cause impaired channel function are associated with a
variety of human diseases, generally known as channelopathies.
Channelopathies affect the nervous, cardiovascular, respiratory,
endocrine, urinary, and immune systems.
Many years of intense research have focused on how
changes in ion channels’ biophysical properties can induce
drastic physiological changes at the cellular and tissular levels,
subsequently causing severe and even lethal human diseases.
The ultimate goal of this research is the development of specific
targeted pharmacotherapies to treat channelopathies. Perhaps the
most well-known example of such a therapy is the treatment
of cystic fibrosis patients with corrector and potentiator drugs
that specifically target the Cystic Fibrosis Transmembrane
conductance Regulator (CFTR) chloride channel to alleviate
mutations affecting its trafficking, folding, and function.
Although this extraordinary translational development is still in
its infancy, with less than 4 years of clinical use, it has required
over two decades of research to reach the necessary level of
understanding of the biophysical and functional parameters of
the CFTR chloride channel.
Prior to cloning of the first chloride channels (ClC-0 and
CFTR), chloride channels were of little interest to scientists,
as Cl− was considered to be in electrochemical equilibrium
across cell membranes. When studying action potentials, cation
channels (Na+, K+, and Ca2+) were considered the major
players; Cl− flux was seen as a mere nuisance. Chloride
movement across membranes can change both the concentration
of the substrate, Cl−, and the electrical charge between the
compartments. As an electronegative ion, chloride plays an
important role in regulating the excitability of neurons and
muscles through changes in the membrane potential. In epithelia,
the Cl− concentration gradient drives the direction of ion
movement through ion transporters, which helps maintain intra-
and extra-cellular osmotic homeostasis. The cloning of the CFTR
chloride channel (Riordan et al., 1989) and the Torpedo electric
organ voltage-gated chloride channel ClC-0 (Jentsch et al., 1990)
were important breakthroughs in chloride channel research,
paving the way for subsequent high impact publications on
chloride transport. ClC-0 was not characteristic of any other
chloride transporter previously described, and thus became the
first member of the new ClC chloride channel family. Nine
mammalian ClC proteins have been identified since the discovery
of ClC-0. Four of these ClCs are expressed in the plasma
membrane and operate as channels (Table 1), and the other
five are Cl−/H+ exchangers localized to intracellular membranes
(Table 2). The ClC family of Cl− transporters is the focus of this
review.
THE ClC FAMILY
The discovery of Torpedo ClC-0 channel by Jentsch et al. (1990)
garnered the attention of the scientific community toward the
ClC protein family. ClC proteins occur in all phyla, with nine
members present in mammals (ClC-1 to ClC-7, ClC-Ka, and
ClC-Kb). Three of the ClC proteins contain a β-subunit (ClC-
Ka, ClC-Kb, and ClC-7), which is essential for proper transport
function, and another member (ClC-2) contains a non-essential
β-subunit that changes its gating properties (Jentsch, 2015).
Although Jentsch et al. (1990) cloned the first ClC member,
the Miller group discovered most of the surprising and unique
properties of this family prior to this. Observations of single
channel current recordings from Torpedo electroplax Cl−
channels demonstrated an unusual gating behavior, with bursts
containing two open conductance levels spaced by long periods
of channel closing (Miller, 1982; Hanke and Miller, 1983). Since
one conductance level was the double of the other, they assumed
that the channel functions as a dimer, with each subunit having
its own independent ion pathway (protopore). Gating of one or
both subunits’ protopores explained the two distinct conductance
levels observed; meanwhile, the single closed state suggested that
despite the two protopores functioning independently, some as-
yet-unknown mechanism closed them simultaneously (Richard
and Miller, 1990). In this now well-established double-barrel
model there is a fast gate (opening and closing events within a
burst) occurring on a time scale of milliseconds and a slow (also
called common) gate, in which both protopores are closed on a
time scale of seconds, reflecting the single closed state observed
in single channel analysis. All channel properties identified by
Miller’s group were afterward attributed to the ClC family of
chloride channels.
In ClCs—unlike cation channels, whose gating is regulated
by voltage sensors controlled by the membrane potential—
the permeant ion (Cl−) is itself responsible for the voltage-
dependent gating, and protons influence the gating (Richard
and Miller, 1990; Pusch et al., 1995; Bezanilla, 2008). That is,
intra- and extra-cellular changes in Cl− concentration and pH
modulate ClC channel function. In general, ClC channels have
an anion selectivity sequence of Cl− > Br− > I− and are largely
impermeable to cations (Jentsch et al., 1995; Fahlke et al., 1997a,b;
Rychkov et al., 1998).
In another surprising discovery, researchers have determined
that while all ClC proteins share the same basic structure,
some function as chloride-proton exchangers with a 2Cl−/1H+
stoichiometry, instead of classical chloride channels (Accardi
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TABLE 1 | Mammalian ClC chloride channels.
Isoform Tissue Function Human disease Knock-out mice
Cl− channels
(cell surface)
ClC-1 Skeletal muscles Recover resting
membrane potential
Myotonia congenita Myotonia congenita
(Steinmeyer et al., 1991a)
ClC-2/
(GlialCAM)
Brain; kidney; liver; heart;
pancreas; skeletal muscles;
lungs and GI tract
Transepithelial transport Leukodystrophy,
azoospermia
Retinal and testes
degeneration; leukodystrophy
(Bösl et al., 2001)
ClC-Ka/Barttin Inner ear; Kidney Transepithelial transport Loss of Barttin or both
ClC-Ks: Bartter IV (renal
salt loss and deafness
Diabetes insipidus (Matsumura
et al., 1999)
ClC-Kb/Barttin Loss of ClC-Kb: Bartter III
(renal salt loss)
The table illustrates tissue expression, function and pathologies related to dysfunction or absence of ClC channels from plasma membranes. Both ClC-K a and b isoforms
require Barttin as an obligatory β-subunit for trafficking, stability and function. GlialCAM is a non-essential β-subunit of ClC-2 and, when associated, change ClC-2
localization and properties in glial cells.
TABLE 2 | Mammalian ClC chloride exchangers.
Isoform Tissue Function Human disease Knock-out mice
Cl−/H+ exchangers
Intracellular
(Endo/lysosomes)
ClC-3 Broad Ion homeostasis of intracellular
vesicles
Retinal and brain degeneration
(Stobrawa et al., 2001;
Dickerson et al., 2002;
Yoshikawa et al., 2002)
ClC-4 Skeletal muscles; brain
and heart
Ion homeostasis of
endosomes?
Intellectual disabilities?
ClC-5 Kidney; intestine Ion homeostasis of early
endosomes
Dent’s disease Impaired renal endocytosis
(Piwon et al., 2000; Wang et al.,
2000)
ClC-6 neurons Ion homeostasis of late
endosomes
Lysosomal storage disease
(Poët et al., 2006)
ClC7/
Ostm1
Brain; kidney; liver and
bone
Acidification of resorption
lacuna in osteoclasts; ion
homeostasis of lysosomes
Osteopetrosis, retinal
degeneration, lysosomal
storage disease
Osteopetrosis; retinal
degeneration; lysosomal
storage disease (Kornak et al.,
2001)
The table illustrates tissue expression, function and pathologies related to defect or absence of the respective ClC exchangers from vesicles of the endosomal/lysosomal
pathway. ClC-7 needs Ostm1 as an essential β-subunit to be stable and functional at lysosomal membranes.
and Miller, 2004; Picollo and Pusch, 2005; Scheel et al., 2005).
In mammals, five ClC proteins function as Cl−/H+ exchangers
(ClC-3 to ClC-7) and are generally localized to intracellular
membranes, while the other four (ClC-1, ClC-2, ClC-Ka, and
ClC-Kb) function as bona fide chloride channels, strictly localized
to the plasma membrane.
Malfunctions in chloride conductance or Cl−/H+
translocation are causes of genetically inherited diseases
(Puljak and Kilic, 2006; Planells-Cases and Jentsch, 2009; Kim,
2014; Stölting et al., 2014b; Jentsch, 2015).
ClC Protein Structure
In 2002, high-resolution crystal structures of two bacterial
ClC exchangers were resolved (EcClC from E. coli and StClC
from S. typhimurium). Exhibiting a complex topology, each
ClC subunit has 18 α-helices that are variable in length
and remarkably tilted. Most of the α-helices fail to traverse
the membrane and display an internal anti-parallel repeat
architecture. This intriguing arrangement of helices makes it
possible for residues from distant parts of the protein to come
together at the center of the subunit, forming the ion selectivity
filter for Cl− conductance (Dutzler et al., 2002, 2003).
In Dutzler’s StClC structure, each ClC subunit has three highly
conserved Cl− binding sites, which feature a partial positive
charge formed by amino acid residues located in the N-terminal
portion of specific α-helices (D, F, N, and R). In the crystal
structure, Cl− could be found at three specific sites made up
by these amino acids: (1) an internal site (Sint) in contact with
the intracellular environment, (2) a central site (Scen) buried
in the membrane bilayer, and (3) an external site (Sext) in
contact with the extracellular solution. In this structure, Sint
and Scen are occupied by Cl− ions, whereas Sext is occupied
by the negatively charged side-chain of a conserved glutamate
(E148; helix F) named Gluext. In Scen, Cl− ions are coordinated
mainly by residues S107 (helix D) and Y445 (helix R), also
called Sercen and Tyrcen, respectively. A Cl− ion occurs in Sext
only following mutation or protonation of E148, which renders
ClC gating proton-dependency. Importantly, mutation of this
glutamate residue (E148Q, which mimics protonation of the
carboxylate side chain) abolishes voltage and chloride-dependent
gating in ClC channels and uncouples Cl−/H+ exchange, turning
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the proteins into passive chloride conductors (Dutzler et al., 2003;
Accardi and Miller, 2004). E148 has been termed the ‘gating
glutamate,’ given its essential role in ClC protein function.
Some researchers have proposed that Cl− and E148 compete
for Sext, and that Cl− conductance (during the pore opening)
occurs only when the side-chain of E148 is displaced from Sext
by extracellular Cl− (Chen, 2003). Presumably, this is the reason
that ClC gating is dependent on extracellular Cl− concentration.
While the ‘gating glutamate’ in the Sext is suggested to be the
molecular determinant of protopore gating (Dutzler et al., 2003),
S107 in the Scen is thought to contribute to Cl− selectivity, as
mutation of this residue to proline changes anion selectivity to
NO3− (Zifarelli and Pusch, 2009). Sint is located close to where
the intracellular solution bathes the selectivity filter, and residues
in helix D coordinate Cl− ions in this position (Dutzler et al.,
2003).
For ClC exchangers to function, a proton pathway is also
required, although there is currently no consensus on how
protons cross the transport pathway. A glutamate residue (E203),
located at the intracellular interface (named Gluint) is suggested
to be the proton acceptor coupling H+ and Cl− transport, as
mutation of this residue abolishes proton transport (Accardi
et al., 2005). Gluext is conserved in both channels and exchangers
and is involved in both Cl− and H+ conductance, whereas
Gluint is only conserved in exchangers and participates only
in H+ transport (Accardi and Miller, 2004; Accardi et al.,
2005). Concurrent mutation of the intracellular and extracellular
glutamates leads to a loss of proton transport, although Cl−
transport is still active. Gluint localizes away from the Cl−
selectivity filter, in a region closer to the subunit’s interface.
Although experimental data is lacking, Gluint and Gluext appear
to cooperate to facilitate proton transport. In the proposed
mechanism, Gluint accepts a H+ from one side of the membrane
and transfers it to Gluext, which then completes the translocation
process (Accardi et al., 2005). However, it is not clear how protons
would traverse the gap between Gluint and Gluext, and because of
Gluint localization, the pathways for Cl− and H+ would diverge
in the intracellular side converging only in the extracellular side,
at Gluext.
The first relatively high-resolution structure of a mammalian
ClC channel (a bovine ClC-K) was solved by cryo-electron
microscopy (Park et al., 2016). Bovine ClC-K (henceforth, bClC-
K) shares 84% sequence similarity with human ClC-K channels
and is only functional when co-expressed with the β-subunit
barttin. bClC-K contains a valine residue (V166) substituted for
Gluext, which causes the channel to have a linear current–voltage
relationship (Park et al., 2016). Based on sequence homology
the structure of bClC-K is predicted to be similar to other ClC
family members (Dutzler et al., 2002, 2003; Feng et al., 2010).
However, the high-resolution structure reported by Park et al.
(2016) suggests some marked differences. bClC-K contains two
extracellular loops, one connecting helices K and M and the
other connecting helices I and J. Both loops are located at the
extracellular entrance of the chloride pathway with the latter
loop in close proximity to the Cl− selectivity filter. There is
also a cytosolic loop connecting helices C and D that displays
a unique conformation from ClC transporters. In bClC-K the
loop contains Sercen (S121 in ClC-K), which faces the cytosolic
side, whereas in ClC transporters Sercen is found facing Scen
interacting with a Cl− ion together with Tyrcen (Park et al.,
2016). Based on these structural differences between bClC-K
and ClC transporters the authors propose a hypothesis for the
different mechanisms underlying ClC channel and transporter
conductance. They suggest that in transporters Sercen and Tyrcen
form a kinect barrier (a constriction) in the middle of the Cl−
pathway preventing Cl− leak uncoupled to H+ during a transport
cycle. In ClC channels they suggest that the unique positioning of
Sercen relieves the kinect barrier allowing higher Cl− conductance
(Park et al., 2016).
The most well studied plant ClC protein is the anion/proton
exchanger AtClC-a, from Arabidopsis thaliana. AtClC-a
promotes the exchange of NO3 rather than Cl− due to a
substitution of Sercen to proline (Zifarelli and Pusch, 2009).
AtClC-a shows outwardly rectifying currents and a 2NO3/1H+
stoichiometry when expressed in isolated vacuoles, similar to
animals and prokaryotes ClC exchangers (De Angeli et al., 2006).
Gluext and Gluint are conserved in AtClC-a and inactivation of
those residues produces similar effect as in the intracellular ClCs
4 and 5 (Bergsdorf et al., 2009).
Cytoplasmic Domains
All eukaryotic ClCs (and some prokaryotic ClCs) have a large
cytoplasmic domain involved in modulating the trafficking and
function of ClC proteins (Estévez et al., 2004; Hebeisen et al.,
2004). Mutations in the cytoplasmic domains cause severe defects
in slow gating, and are also associated with human genetic
diseases (Fong et al., 1998; Estévez et al., 2004; Puljak and
Kilic, 2006; Planells-Cases and Jentsch, 2009; Kim, 2014; Stölting
et al., 2014b). The crystal structures of cytoplasmic domains
from ClC-0, ClC-Ka, and ClC-5 have been resolved; cytoplasmic
domains of each subunit contain two CBS domains that interact
with one another via an extensive interface. The CBS domains
also interact with the transmembrane part of the same subunit,
and with CBS domains of the other subunit. Additionally, the
cytoplasmic domains display a dimeric organization resembling
the transmembranal architecture (Meyer and Dutzler, 2006;
Markovic and Dutzler, 2007; Meyer et al., 2007; Feng et al., 2010;
Park et al., 2016).
The cytoplasmic domains connect with the α-helix R, which
contains Tyrcen that participates directly in Cl− coordination
during transport. As mutations in the cytoplasmic domains are
involved in genetic diseases, several studies have addressed the
influence of alterations in the cytoplasmic domains in channel
gating behavior. A point mutation downstream of the second
CBS domain (A885P) in ClC-1 results in a dramatic reduction in
channel open probability at voltages near the optimal membrane
potential for ClC-1 to function (Beck et al., 1996). Two truncated
ClC-1 mutants (R875X and K894X), the first removing the
whole region downstream of CBS2 and the second mimicking
a naturally occurring mutation in myotonic patients, display
changes in anion binding affinity, resulting in changes in the
voltage dependence for both fast and slow gates (Hebeisen and
Fahlke, 2005). He et al. (2006) analyzed two splice variants of
Caenorhabditis elegans ClC channel, CLH3a and CLH3b, which
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display marked gating differences. CHL3a has a N-terminal splice
insertion that when deleted do not alter gating properties. CHL3b
has two splice insertions at the cytoplasmic domains, one between
the two CBS domains and the second distal to CBS2. Deletion
of either the insertion distal to CBS2 or the last 11 amino acids
of CBS1 gives rise to channels with gating properties similar
to CHL3a (He et al., 2006). Those studies demonstrate that
alterations at the cytoplasmic domains modify the conformation
of the pore affecting channel gating.
Cytoplasmic domains of some ClC proteins interact with
adenosine nucleotides. In ClC-1, binding of intracellular ATP
inhibits the channel by stabilizing it in its closed state (Bennetts
et al., 2005). ATP binding has the opposite effect in ClC-5
exchangers, activating the transporter. Binding of ATP to ClC-2
slows down the rate of activation and deactivation, but does
not affect the maximal open probability of the channel (Stölting
et al., 2013). Nucleotides bind at the interface between the two
CBS domains, as revealed by the crystal structure of ClC-5.
The nucleotide binding site has no catalytic properties, and to
it AMP, ADP, and ATP bind with equal affinity (Meyer et al.,
2007). There are no apparent nucleotide binding sites in the
cytoplasmic domains of ClC-0 or ClC-Ka (Meyer and Dutzler,
2006; Markovic and Dutzler, 2007). Interestingly, the cytoplasmic
domains of the plant ClC AtClC-a also interacts with adenosine
nucleotides. At this exchanger, ATP reduces transport activity by
a maximum of 60%. Unlike ClC-5, only ATP produces this effect,
with AMP working only as a competitor limiting ATP inhibition
when present in solution (De Angeli et al., 2009).
The antiparallel dimerization observed with the CBS domains
of ClC proteins following ATP binding is a feature also seen in
the CFTR chloride channel, in which ATP binds at two conserved
motifs at the interface of two intracellular nucleotide binding
domains. These domains dimerize in a head-to-tail conformation
leading to channel gating and chloride movement following
conformational changes. By analogy, one may speculate that
adenosine nucleotide binding to the CBS domains could cause
protein rearrangements that affect channel behavior in some
ClCs.
Common Gating
In contrast to the well-studied fast gating mechanism of ClC
proteins, the molecular mechanism of the slow (common) gate
is still obscure. Evidence suggests that extensive conformational
rearrangements in the protein could contribute to the slow gate
(Pusch et al., 1997; Duffield et al., 2005; Bykova et al., 2006;
Ma et al., 2011). Two facts support the idea that conformational
changes promoted by the cytoplasmic domains may lead to
the movement of critical transmembrane helices and play an
important role in the common gating mechanism. First, point
mutations at helices localized at the dimer interface cause
changes in common gating (Duffield et al., 2003). Second, the
crystal structure of the eukaryotic ClC transporter show relevant
connections between the CBS domains and helices H and I,
localized at the dimer interface (Feng et al., 2010).
Another interesting hypothesis suggests that ClC channels
likely behave as ‘broken’ exchangers in which proton transport
is involved in the common gating, suggesting that the
conformational changes of channels’ common gating and
coupled Cl−/H+ transport have an evolutionary linkage (Lísal
and Maduke, 2008). Since gating of ClC-0 channels is not in
a thermodynamic equilibrium (Richard and Miller, 1990), the
authors demonstrated that proton transport is involved in ClC-0
gating and is, in fact, the source of energy that keeps ClC channels
in this asymmetric gating state (Lísal and Maduke, 2008). Further
support for this position comes from a study in which a
small but reproducible H+ transport demonstrated in ClC-1
channels was no longer identified in ClC-0 channels carrying the
C212S mutation that abolish common gating (Picollo and Pusch,
2005).
There is evidence for a critical role for the Gluext residue in this
mechanism (Dutzler et al., 2003; Cederholm et al., 2010), which
would make this residue an essential part of both gating processes
in ClC channels and also in the Cl−/H+ ion translocation in
ClC exchangers. Feng et al. (2010) proposed a hypothesis for
the mechanism of coupled Cl−/H+ transport, in which Gluext
cycles between Sext, Scen, and the extracellular environment.
While occupying Scen, Gluext interacts with Tyrcen and accepts
a proton from the intracellular H+ pathway. Then, following a
conformational change after protonation, it would deliver the H+
to the extracellular solution. Presupposing that common gating
and Cl−/H+ translocation are evolutionarily linked, and using
the Cl−/H+ transport mechanism described above as a model,
Bennetts and Parker (2013) suggested that Gluext and Tyrcen
play an important role for ClC-0 and ClC-1 common gating as
they do for Cl−/H+ translocation. Additionally, they proposed
that conformational changes for closure of the common gating
involve helices G, F, H, I, and the CBS2 domain of the adjacent
subunit, resulting in an arrangement that places Gluext (helix F)
in position for hydrogen bonding with Tyrcen (helix R), locking
the channel closed. In this model, helix G would function as the
coordinator between protopore and subunit interface, integrating
both subunits for the common gating.
In the same work, the authors reported the involvement of
Tyrcen in Zn+2 inhibition and NAD+modulation of the common
gate (Bennetts and Parker, 2013). This research sheds some light
on the molecular determinants of the common gating of ClC
channels, but much remains unclear. The pathway for the H+
transport—proposed to be involved in the common gating—
is not yet defined, as the suggested intracellular coordinator
(Gluin) is changed by a valine residue in ClC channels. Also,
in the eukaryotic CmClC Cl−/H+ exchanger, Gluin is replaced
by a threonine residue that either perform this transport or
this exchanger would use an alternative H+ pathway (Feng
et al., 2010). A neighboring conserved Glu residue (E291 in
ClC-1), however, was proposed as a substitute to execute this
function (Lísal and Maduke, 2009). Mutation to a protonable
aspartate (E291D) shifted voltage dependence to more positive
values but preserved the pH dependence, whereas mutation to
a neutral glutamine (E291Q) remarkably reduced voltage and pH
dependence, suggesting the participation of this residue in the H+
transport (Lísal and Maduke, 2009). This assumption, however,
cannot be confirmed based solely on mutagenesis experiments.
The exact molecular rearrangement necessary for the common
gating is another puzzle, with many parts still missing.
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One recent study analyzing ClC-1/ClC-2 heterodimeric
channels revealed channels with original gating properties. The
common gating was abolished, with each subunit displaying
individual slow gates as well as independent fast gates (Stölting
et al., 2014a). These findings suggest that conformational changes
underlying common gating mechanisms may originate within
each protopore gate, and that fast and slow gating may in
fact be linked mechanisms (Bennetts and Parker, 2013; Stölting
et al., 2014a). Homodimeric channels are able to coordinate
both slow gates, resulting in a single common gating, whereas
heterodimeric channels lack this coordination and display
individual slow gating for each subunit (Figure 1).
Importance of ClC Channels and
Exchangers in Cell Homeostasis
ClC proteins are important for a number of physiological
processes. In skeletal muscle, sodium and potassium channels
provide the influx and eﬄux of cations necessary for propagation
of the action potential, and the Cl− current generated by ClC-1 is
critical for proper re-polarization of the muscle fiber (Steinmeyer
et al., 1991a; Stölting et al., 2014b). Impairment of ClC-1 function
leads to myotonia, a condition characterized by delays in muscle
relaxation after a contraction (Planells-Cases and Jentsch, 2009;
Imbrici et al., 2015). ClC-2 in enterocytes and ClC-Kb in the
thick ascending limb of Henle’s loop, working in concert with
Na+-K+-ATPase, are necessary for Na+ and Cl− transport from
the lumen to the interstitium (Uchida et al., 1995; Estévez et al.,
2001; Catalán et al., 2004). In the inner ear, K+ accumulation in
the endolymph (critical for inner hair cell sensory transduction)
mediated by KCNQ1/KCNE1 K+ channels is only possible
because ClC-K channels recycle the Cl− accumulated into the
cell (by the action of Na+-K+-Cl− co-transporter) back to the
interstitial fluid (Rickheit et al., 2008).
In vesicular membranes of the endosomal/lysosomal pathway,
Cl−/H+ exchange mediated by ClCs is required for vesicular
acidification, which is necessary for endocytosis, vesicle sorting
and lysosomal digestion (Piwon et al., 2000; Hara-Chikuma et al.,
2005a; Kasper et al., 2005; Lange et al., 2006; Weinert et al., 2010).
In all tissues and subcellular compartments described above, and
many others, ion channel and transporter activity combines to
maintain homeostasis. Dysfunction in even one component of
the system can lead to drastic ion imbalances that may culminate
in local or systemic diseases. In the case of ClC proteins, impaired
function of ClC-1, ClC-2, ClC-K, ClC-5, and ClC-7 may result
in myotonia congenita, azoospermia/leukodystrophy, Bartter
syndromes types 3 and 4, Dent’s disease, and osteopetrosis/retinal
degeneration/lysosomal storage disease, respectively.
MAMMALIAN ClCs AND HUMAN
DISORDERS
ClC-1: A Skeletal Muscle Chloride
Channel
ClC-1 was the first mammalian ClC channel identified using
homology cloning from the Torpedo ClC-0 channel. ClC-1
is expressed almost exclusively in skeletal muscle (Steinmeyer
et al., 1991b), and has the same double-barreled conformation
reported for ClC-0, although with a considerably smaller
conductance. Activation of the fast and slow gating of ClC-1
requires depolarization that is dependent on the Cl− and H+
concentration (Fahlke et al., 1996; Saviane et al., 1999). Adenosine
nucleotides’ inhibition of CLC-1 is regulated by oxidation and
reduction. Thus, ATP inhibits only reduced ClC-1 channels
by shifting the voltage-dependence of common gating to more
positive potentials; this inhibition disappears upon oxidation of
ClC-1 (Zhang et al., 2008). Nucleotides bind in a putative site
formed by residues from both CBS domains, and this inhibition
is enhanced by low intracellular pH (Bennetts et al., 2005, 2012).
This may be the mechanism by which the muscle fiber regulates
channel function depending on the metabolic state. PKC and
Zn+2 were also found to modulate ClC-1 function. Blocking
by Zn+2 is closely related to the slow gating process. Mutation
C277S locks the slow gate opened and abolishes the Zn+2 blocker
effect, whereas mutation V321A reduces slow gating opening and
facilitates Zn+2 blocking, suggesting that the effect of this ion is
dependent on the state of the slow gating (Duffield et al., 2005).
Several serine residues were identified in the C-terminal portion
of ClC-1 that may mediate PKC modulation of the channel
function (Hsiao et al., 2010). PKC activators inhibit the channel,
whereas PKC inhibitors increase the current, suggesting that PKC
phosphorylation of the C-terminal portion is important for ClC-
1 function (Brinkmeier and Jockusch, 1987; Tricarico et al., 1991;
Camerino et al., 2014).
ClC-1 and Myotonia Congenita
Skeletal muscle has a uniquely high resting Cl− conductance
that is more than four times greater than the K+ conductance
(Bretag, 1987). ClC-1 is the predominant mediator of the
Cl− conductance in skeletal muscle. The first insight into the
physiological role of ClC-1 came from studies using myotonic
goats (Lipicky and Bryant, 1966) and myotonic adr mice
(Steinmeyer et al., 1991a). Skeletal muscle fibers from these
animals failed to repolarize following repeated action potentials,
resulting in the so-called ‘myotonic after-discharge’ condition,
characterized by muscle stiffness (Adrian and Bryant, 1974).
After an action potential, Na+ channels close and K+ channels
open to allow the ion eﬄux necessary for repolarization. In
the T-tubules this K+ accumulation (increasing of [K+]ext)
may generate small depolarizations even after inputs from the
nervous system have ceased. ClC-1 mediates Cl− conductance
that prevents the K+-mediated depolarization from propagating
along the sarcolemma (Figure 2). In myotonic fibers, the lack of
ClC-1 conductance leads to autonomous fiber action potentials
that keep the muscle active, delaying relaxation (Steinmeyer et al.,
1991a; Stölting et al., 2014b). Mutations in the ClC-1 gene were
found in families with myotonia congenita. These mutations
lead to partial or complete loss of function of ClC-1, affecting
channel function in different ways depending on the mutation.
A group of mutations cause a reverted voltage dependency,
i.e., D136G (Fahlke et al., 1995), G499R (Zhang et al., 2000),
C277Y (Weinberger et al., 2012), G523D (Ha et al., 2014). These
mutations cause the channels to activate upon hyperpolarization
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FIGURE 1 | Flowchart of the proposed new gating behavior of ClC-1/ClC-2 heterodimers (Stölting et al., 2014a). Homodimers present individual fast
gating for each subunit and a single common gating generated by the coordination of each subunit’s slow gating. In the heterodimer assembly (center), the individual
protopore gating is maintained whereas coordination of each subunit’s slow gating is missing. In those channels each subunit displays individual slow gating (with
distinct time and voltage dependence), therefore, the common gating is not observed.
rather than deactivate like wild-type ClC-1, rendering channels
with dramatically reduced or abolished currents at physiological
chloride gradients. Mutation G230E (Fahlke et al., 1997a) and
the aforementioned C277Y alters the ion selectivity of the
channel pore. The A531V has normal gating properties but
has reduced expression at the plasma membrane due to an
increased degradation rate (Lee et al., 2013). It was later shown
by Chen et al. (2015) that a ubiquitin ligase complex (CUL4A/B-
DDB1-CRBN) ubiquinates the A531V mutant leading to its
subsequent degradation. To date, more than 130 mutations have
been identified in the gene encoding ClC-1, and heterologous
expression of mutated channels has played a valuable role in
helping scientists to understand channel structure and function
and disease pathogenesis (Matthews et al., 2010; Imbrici et al.,
2015).
Myotonia congenita is the most common skeletal muscle
hereditary channelopathy in humans, characterized by an
atypical delay in muscle relaxation after voluntary contractions,
called muscle stiffness. The myotonic stiffness is worse after
rest, and improves after repetitive movements, referred as
the warm-up phenomenon (Thomsen, 1876; Bryant, 1973). In
humans, myotonia can be inherited as a dominant (Thomsen
disease) or a recessive (Becker disease) trait, with more severe
symptoms found in the latter form (Saviane et al., 1999). In the
dominant form, mutant subunits exert a dominant negative effect
on wild-type subunits; that is, the mutant impairs (at variable
levels) the function of the wild-type subunit.
Using the crystal structure of cmClC (an eukaryotic ClC
exchanger) (Feng et al., 2010) as a model for human ClC-1
allowed the identification of residues found mutated in myotonic
patients in the dimer interface and in the ion conduction
protopore (Skálová et al., 2013). Moreover, mutations causing
the dominant-negative effect were located in or proximal to
the dimer interface region. Meanwhile, mutations affecting the
channel protopore do not exert the dominant-negative effect
(Skálová et al., 2013). As the slow gating involves subunit
interactions at the dimer interface, mutations affecting this area
in only one subunit prevent the coordination necessary for the
common gating and explain the impairment of the adjacent wild-
type subunit. In the recessive form, both subunits are affected and
ClC-1 currents may be abolished completely, leading to the more
severe symptoms reported (Saviane et al., 1999; Imbrici et al.,
2015).
To date, there is no specific treatment for patients with
myotonia congenita. To surpass ClC-1 defect, the ideal drug
should specifically enhance its Cl− currents; unfortunately, this
objective seems to be far from completion (Imbrici et al., 2015).
One early study showed that the R-isomer of CPP, a clofibric
acid derivative, was able to increase Cl− conductance in voltage
clamp recordings of muscle fibers (De Luca et al., 1992). This
activity was not recognized in heterologously expressed channels,
suggesting that the drug does not interact directly with ClC-1
and probably uses a muscle-specific component to exert its
effect (Pusch et al., 2000). Acetazolamide (a carbonic anhydrase
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FIGURE 2 | ClC-1 is a major ion channel involved in the membrane resting potential of skeletal muscles. Action potentials, from motor neurons, causes
the opening of L-type calcium channels (DHPR) that in turn open intracellular channels (RyR). Calcium release from both channels increases sarcoplasmic reticulum
[Ca2+] necessary for muscle contraction. After contraction, K+ efflux repolarizes the membrane. ClC-1 chloride conductance prevents K+ accumulation at the
T-tubules from propagating along the sarcolemma and trigger undesirable autonomous depolarizations.
inhibitor) was also reported to be able to shift the voltage-
dependence of ClC-1 channel opening to more negative voltages,
possibly through changes in intracellular pH, consequently
enhancing Cl− conductance. However, this potentially anti-
myotonic effect was not effective in some mutant channels
(Eguchi et al., 2006; Desaphy et al., 2013).
ClC-2: A Widely Expressed ClC Channel
The discovery of ClC-2 came soon after ClC-1. ClC-2 is
approximately 50% identical to ClC-1, and is expressed in the
plasma membrane of cells from a variety of tissues, including
the brain, kidney, pancreas, skeletal muscles, heart, lungs, gastro-
intestinal tract, and liver (Thiemann et al., 1992). ClC-2 opens
in a very short time course upon hyperpolarization. Its voltage-
dependent gating is modulated by the concentration of Cl− and
H+. Increase in the intracellular concentration of Cl− shifts the
voltage-dependence to a more positive voltage, activating the
channel. ClC-2 is also activated by mild decreases in extracellular
pH, although a further decrease in pH reduces current (Niemeyer
et al., 2004).
ClC-2 can bind to the accessory molecule GlialCAM, an
adhesion molecule, in several glial cell types. This interaction is
not required for the channel to function, but rather modifies the
channel gating properties (Jeworutzki et al., 2012). GlialCAM also
binds to Mlc1 (a membrane protein involved in megalencephalic
leukoencephalopathy with subcortical cysts, a type of
leukodystrophy) and docks both complexes (GlialCAM-ClC-2
and GlialCAM-Mlc1) at cell-cell junctions (López-Hernández
et al., 2011; Jeworutzki et al., 2012; Hoegg-Beiler et al., 2014).
Co-expression of GlialCAM with ClC-2 increases currents and
almost eliminates the inward rectification, rendering ClC-2
channels nearly constitutively open (Jeworutzki et al., 2012).
Disruption of either GlialCAM or Mlc1 affects the expression
and localization of ClC-2 (Hoegg-Beiler et al., 2014). Mutations
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of either GlialCAM or Mcl1 genes lead to megalencephalic
leukoencephalopathy, a type of leukodystrophy characterized
by early-onset macrocephaly and delayed-onset neurologic
deterioration, symptoms comparable to the neurological
phenotype of ClC-2 disruption (López-Hernández et al., 2011).
ClC-2 gating is affected by ATP and, like ClC-1, ATP changes
the voltage dependence of the common gating. Whole-cell patch
clamp recordings show slow activation and deactivation times.
Single channel recordings exhibit longer periods of closed states
of the common gating when high levels of intracellular ATP
are present. This effect, however, does not change the open
probability of the channel (Stölting et al., 2013).
ClC-2 in Azoospermia and Leukodystrophy
In the testes, tight junctions between Sertoli cells isolate the
adluminal compartment of the seminiferous tubules from the
blood irrigation (blood–testis barrier). Because of this barrier,
maturation and differentiation of spermatogonia into sperm cells
require a close physical contact with Sertoli cells that are also
responsible for the nourishment of the germ cells during this
process. Disruption of ClC-2 function results in transepithelial
transport defect in Sertoli cells and subsequent degeneration of
male germ cells (azoospermia), as observed in ClC-2 knock-out
(KO) mice (Bösl et al., 2001; Bi et al., 2013).
ClC-2 KO mice also develop leukodystrophy (the general term
for diseases affecting the growth or maintenance of the white
matter), which culminates with gradual development of vacuoles
in the myelin sheath of the central nervous system, worsening
with age (Blanz et al., 2007). Human patients carrying mutations
that disrupt ClC-2 function develop similar leukodystrophy
symptoms (Depienne et al., 2013); in one patient, azoospermia
was found together with a subclinical leukodystrophy (Di Bella
et al., 2014). This was the first case report demonstrating
azoospermia and leukodystrophy in a patient with ClC-2
mutation.
Other Controversial Physiological Roles
ClC-2 is also expressed in epithelial cells of the gastrointestinal
tract and lungs. In the past, ClC-2 was proposed to play a role
in Cl− eﬄux at the apical membrane of epithelial cells of these
tissues, working as an alternative pathway to CFTR-dependent
Cl− secretion. However, the intestinal phenotype observed in
CFTR-KO mice was not aggravated in double KO mice, in the
absence of both CFTR and ClC-2. Instead, double KO mice
survived better than CFTR-KO mice (Zdebik et al., 2004). Later
on, it was demonstrated that ClC-2 localizes at the basolateral
membrane of enterocytes, facilitating water and salt absorption
(Figure 3) (Catalán et al., 2004). In the basolateral membrane,
ClC-2 is proposed to move Cl− in the opposite direction of
CFTR, e.g., moving Cl− from the cell to the interstitium.
Loss of ClC-2 in CFTR-KO mice would then increase Cl−
concentration inside the cell, facilitating Cl− eﬄux in the apical
compartment by an alternative pathway and compensating for
the loss of CFTR from the apical membrane. These and other
reports (Catalán et al., 2004; Peña-Münzenmayer et al., 2005)
provide convincing data for the basolateral localization of ClC-
2 in intestinal epithelia. ClC-2 could play the same role in the
FIGURE 3 | ClC-2 aids in water absorption in intestinal epithelia. In
colonic enterocytes, chloride absorbed from the intestinal lumen (via SLC26A3
chloride/bicarbonate exchanger) is transported to the interstitium through
ClC-2. Sodium enters the cell via ENaC channels or sodium/proton
exchangers and is transported to the interstitium through the Na+/K+ ATPase.
High NaCl gradient at the interstitium induces osmotic water absorption from
the lumen.
lung epithelium, although its precise localization is still not
conclusive.
ClC-2 is also expressed in neurons and glial cells, where
it is proposed to lower the intracellular concentration of Cl−.
ClC-2 would be activated after a Cl− influx mediated by
hyperpolarizing GABA currents. ClC-2, then, would extrude
the excess of intracellular Cl− down to its electrochemical
equilibrium helping in the maintenance of a Cl− gradient
favorable to cell hyperpolarization by GABA currents (Staley
et al., 1996; Földy et al., 2010; Rinke et al., 2010). This theory,
however, was questioned by a study using a computational
model—based on ClC-2 parameters previously characterized
in CA1 pyramidal cells—simulating physiological conditions
which showed ClC-2 actually mediating chloride influx, directly
reducing cell excitability (Ratté and Prescott, 2011).
The retinal pigment epithelia (RPE) are responsible for
forming the blood–organ barrier in the eye, creating the optimal
microenvironment for photoreceptor function. Loss of retinal
photoreceptors induces retinal degeneration. Loss of ClC-2
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function has been proposed to affect transepithelial transport
in the RPE by disrupting microenvironment ion homeostasis,
resulting in photoreceptor degeneration (Bösl et al., 2001;
Bi et al., 2013). Studies on ClC-2 KO mice revealed retinal
degeneration, indicating an important role for this channel in
RPE. This degenerative phenotype suggests the disruption of ion
homeostasis in this tissue (Bösl et al., 2001).
Previously, several other functions were thought to be
assigned to ClC-2. Suggested roles in gastric acid secretion
(Sherry et al., 2001) and lung development (Murray et al., 1995)
were supported neither by experimental data nor by ClC-2 KO
mice phenotype. A role in epilepsy was also considered, but after
the retraction of a widely cited paper correlating ClC-2 mutations
to idiopathic generalized epilepsy, there is no credible evidence
for a ClC-2 role in human epilepsy. This is consistent with the
lack of seizures observed in ClC-2 KO mice (Bösl et al., 2001;
Blanz et al., 2007).
ClC-Ka and ClC-Kb: Largely Open ClC
Channels That Require a β-Subunit
ClC-Ka and ClC-Kb (-K1 and -K2 in rodents) are two closely
related ClC channels (around 90% identical) (Adachi et al., 1994;
Kieferle et al., 1994), expressed almost entirely in nephrons and
in the stria vascularis of the inner ear (Uchida et al., 1995;
Estévez et al., 2001). Different from the other mammalian ClC
channels, the two ClC-K isoforms lack the ‘gating glutamate,’
displaying halide selectively sequence of Br− > Cl− > I−
(Adachi et al., 1994). ClC-K channels have only a slight voltage-
dependent gating and hence are open over a broad voltage range
(Estévez et al., 2001; Stauber et al., 2012). The first heterologously
expressed ClC-Ka and -Kb channels (and also the mice ClC-K2)
failed to display any conductance (Kieferle et al., 1994), which
raises questions about the necessity of a β-subunit, given that
immunohistochemistry (Uchida et al., 1995; Vandewalle et al.,
1997) and disease-causing mutations (Simon et al., 1997) clearly
indicate their participation in transepithelial salt transport.
Barttin, a 40 kDa and 320-residue protein containing two
transmembrane domains and a long intracellular C-terminal
domain (Birkenhäger et al., 2001) was identified as the required
accessory protein for human ClC-K proteins to be functional
(Estévez et al., 2001). Barttin is essential for channel function,
stability, and trafficking to the correct membrane area within
the cell (Estévez et al., 2001; Waldegger et al., 2002; Scholl
et al., 2006). The transmembrane region of barttin is important
for its association with ClC-K proteins as well as trafficking to
the plasma membrane, whilst the initial part of the C-terminal
domain is essential for channel conductance activation (Scholl
et al., 2006).
To date, there has been little investigation of interactions
between barttin and ClC-K proteins, but two helices of ClC-
K are proposed to interact with the transmembrane domain of
barttin (Tajima et al., 2007). To further investigate the molecular
determinants of barttin/ClC-K interactions, Wojciechowski et al.
(2015) used tryptophan scanning mutagenesis to identify amino
acids in the transmembrane domains of barttin essential for
ClC-K function. Taking into account only normally expressing
barttin mutants (some mutants were misfolded or had low
expression), substitution of six amino acids (three in each of the
transmembrane domains) affected ClC-K/barttin trafficking to
the membrane. In contrast, several mutations directly affected
ClC-K function. ClC-K currents were abolished when co-
expressed with 12 barttin mutants (nine at the first and three
at the second transmembrane domains) while two tryptophan
insertions at the second transmembrane caused reduced current
amplitudes. As most inactivating mutants had tryptophan
insertions at the first transmembrane domain, the authors suggest
that this domain is critical for activation of ClC-K channels
(Wojciechowski et al., 2015).
Co-expressed ClC-K/barttin channels display a very high Cl−
conductance (∼40 pS compared to∼1 pS for ClC-1 and∼3 pS for
ClC-2), modulated by extracellular pH and Ca+2 concentration;
function is inhibited by H+ and activated by Ca+2. However, the
physiological importance of these modulations are still unclear.
ClC-K/barttin localizes at the basolateral membranes of both the
thin and thick ascending limbs of Henle’s loop, and in marginal
cells of the stria vascularis of the inner ear (Estévez et al., 2001).
ClC-K1 was also found in the apical membrane of the thin
ascending limb of Henle’s loop (Uchida et al., 1995).
ClC-K in Renal Salt Loss and Deafness
ClC-Kb/barttin is mainly expressed in basolateral membranes of
the thick ascending limb of Henle’s loop, where it is involved in
the reabsorption of salt and, consequently, water (Uchida et al.,
1995). In this part of the nephron, the Na+ electrochemical
gradient (created by basolateral Na+/K+ pump) drives the
secondary active transport of NKCC2 (present in the apical
membrane), accumulating Na+, Cl−, and K+ into the cell. K+
is extruded back to the lumen through ROMK K+ channels
(also present in the apical membrane), whereas Na+ and Cl− are
reabsorbed by the interstitial fluid through the Na+/K+ pump
and ClC-Kb channels, respectively. Thus, the end product of
this system is the reabsorption of NaCl into the blood stream
(Figure 4A).
In the inner ear, both ClC-K isomers are expressed in the
basolateral membrane of marginal cells of the stria vascularis.
This multilayered epithelium is responsible for both the high
concentration of K+ and the positive potential (about 100 mV
higher than normal extracellular fluids) of the endolymph of
the scala media, both of which are important properties for
hearing. In marginal cells—the more apical layer in the stria
vascularis—Na+/K+ pumps and NKCC1 transporters build up
K+ and Cl− inside the cells. ClC-K/barttin channels recycle Cl−
back to the interstitial fluid, while apical KCNQ1/KCNE1 K+
channels secrete the excess of potassium ions into the endolymph
(Figure 4B) (Rickheit et al., 2008).
In agreement with the transport models involving ClC-
K/barttin channels, mutations in the gene encoding ClC-Kb
cause salt-losing Bartter syndrome type III (Simon et al., 1997),
characterized by hypokalemia, metabolic alkalosis and secondary
hyperaldosteronism with normal or low blood pressure (Andrini
et al., 2015). Mutations in the gene encoding barttin cause Bartter
syndrome type IV that combines the salt waste with congenital
deafness, since both ClC-K proteins are non-functional in the
Frontiers in Pharmacology | www.frontiersin.org 10 March 2017 | Volume 8 | Article 151
fphar-08-00151 March 21, 2017 Time: 15:52 # 11
Poroca et al. ClC Channels in Human Channelopathies
FIGURE 4 | ClC-K channels are expressed in kidney and inner ear. (A) At the nephrons, luminal NKCC2 transporters build up Na+, K+ and Cl- into the cells.
K+ flows back to the lumen through ROMK1 channels; Na+ and Cl- are reabsorbed to the bloodstream separately through Na+/K+ ATPase and ClC-Kb channels,
respectively. (B) In the Stria Vascularis, Na+, K+ and Cl- are transported into the cells by basolateral NKCC1 transporters. Na+ and Cl- are recycled back to the
interstitium by Na+/K+ ATPase and both ClC-Ks isomers, respectively. K+ flows through KCNQ1/KCNE1 channels and accumulates into the endolymph, a condition
required for sensory transduction in inner hair cells.
absence of barttin (Birkenhäger et al., 2001). When disruption
occurs in only one of the ClC-K channels, as it does in ClC-
Kb mutations in Bartter type III, hearing is preserved; the
other isomer channel still provides the necessary Cl− recycling.
Deafness occurs only on disruption of both ClC-K channels or
upon disruption of barttin (Birkenhäger et al., 2001; Schlingmann
et al., 2004).
Although there are no reports of patients presenting
mutations only in ClC-Ka, two patients presenting symptoms
similar to those accompanying Bartter syndrome type IV—severe
renal salt loss and sensorineural deafness—were described with
loss-of-function mutations in both ClC-K isomers instead of
barttin (Schlingmann et al., 2004; Nozu et al., 2008).
ClC-K Involvement in Cardiovascular Diseases
Polymorphisms in ClC-Ka and -Kb genes were described, and
their relationship with cardiovascular diseases was analyzed.
ClC-Kb gene polymorphism T481S increases currents in
heterologously expressed channels by approximately 20-fold
(Jeck et al., 2004). This may lead to increased salt reabsorption
in the thick ascending limb of Henle’s loop, suggesting a possible
connection with hypertension. However, several cohort studies
found discrepant results, and a link between this activating
polymorphism and hypertension is still lacking (Jeck et al., 2004;
Speirs et al., 2005; Fava et al., 2007; Sile et al., 2009). One frequent
polymorphism in the ClC-Ka gene (R83G) was linked to heart
failure. R83G was reported to reduce ClC-Ka currents by about
50%, and was statistically associated with heart failure in three
independent Caucasian cohorts (Cappola et al., 2011). However, a
functional link between this half-loss-of-function polymorphism
and heart failure is still not established.
ClC-K/barttin channels are promising candidates for
therapeutic drugs. As ClC-Kb is involved in salt and water
reabsorption in the thick ascending limb of Henle’s loop, drugs
blocking ClC-Kb/barttin function could reduce renal salt and
water reabsorption, which would decrease blood volume and
consequently reduce blood pressure. In the inner ear, hearing
depends on the depolarization of mechanosensitive hair cells.
Different from other excitable cells that use Na+ currents for
depolarization, depolarization of hair cells is mediated by K+
influx.
Drugs capable of increasing ClC-K/barttin function in the
stria vascularis would increase endolymph K+ concentration, and
therefore could be used to treat hearing disorders. However, due
to expression of ClC-K/barttin channels in both the kidney and
inner ear, it will be difficult to develop specific drugs without
undesirable side effects. Recently, while testing new benzofuran
derivatives designed to block ClC-K function, Liantonio et al.
(2016) described the most potent and selective ClC-K blocker
discovered to date (SRA-36). This compound is able to inhibit not
only wild-type channels, but also the Cl− currents of polymorphic
ClC-K channels associated with hypertension (Liantonio et al.,
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2016). Although several studies have made significant progress
on the identification of compounds modulating ClC-K channel
function (Liantonio et al., 2004, 2006, 2016; Picollo et al., 2004),
there are not yet therapeutic drugs available.
ClC-5: A ClC Exchanger of Early
Endosomes
ClC-5 is the most well-studied member of the second branch
of the ClC family. It was identified independently by linkage
analysis of patients with Dent’s disease (Fisher et al., 1994) and
by homology cloning (Steinmeyer et al., 1995). Unlike ClC-
3 and ClC-4, ClC-5 has a more restricted tissue distribution,
localizing mostly in renal and intestinal epithelia (Steinmeyer
et al., 1995; Vandewalle et al., 2001). In the kidney, ClC-5
is mostly expressed in acid-transporting intercalated cells in
distal nephron and in PTCs (Günther et al., 1998). In PTCs,
ClC-5 is co-localized with V-type H+-ATPase at early and
recycling endosomes, with only a small amount found at the
surface membrane of brush cells (Günther et al., 1998). In
intestinal epithelia, ClC-5 also co-localizes with the proton
ATPase in apical endosomes (Figure 5) (Vandewalle et al.,
2001).
Although it is mainly localized in apical endosomes, a
reasonable amount of ClC-5 can be found at the cell surface
upon heterologous overexpression, where it can be biophysically
analyzed (Steinmeyer et al., 1995; Friedrich et al., 1999). ClC-5
is a 2Cl−/1H+ exchanger (Picollo and Pusch, 2005; Scheel et al.,
2005) with an anion conductance sequence of Cl− > Br− > I−,
and displays strong outwardly rectifying current that is decreased
by low extracellular pH, similar to the closely related ClC-
4 (Steinmeyer et al., 1995; Friedrich et al., 1999). Similar to
other ClC exchangers, neutralization of the ‘gating glutamate’
results in uncoupled Cl− passive conductance and eliminates
voltage dependence (Picollo and Pusch, 2005; Scheel et al., 2005).
Interestingly, however, the neutralization of Gluint—the putative
intracellular proton acceptor—results in disruption of both Cl−
and H+ transport in ClC-5, creating a transport-deficient protein.
That behavior differs from the prokaryotic exchanger ecClC,
which exhibits Cl− passive conductance upon either ‘gating
glutamate’ or ‘proton glutamate’ mutations (Zdebik et al., 2008).
Grieschat and Alekov (2012) found similar results by neutralizing
either Gluext or Gluint.
When ClC-5 is expressed heterologously, replacement of
extracellular Cl− with SCN− leads to uncoupling of anion
transport but does not affect proton transport. The change from
extracellular Cl− to SCN− led to increased current amplitudes,
and this effect was ∼4-fold higher when intracellular pH was
reduced. The effect of intracellular protons was suggested to be
related to the protonation of Gluext. Neutralizing either Gluext
or Gluint (E211C; E268C) eliminated the effect of low pH. With
neutralization of Gluext the cysteine side chains are not available
for protonation. With neutralization of Gluint cysteine is unable
to supply protons to Gluext (Grieschat and Alekov, 2012). In
the case of the E268C mutant, transport was restored to wild-
type levels after reaction of a negatively charged and protonable
MTSES compound with C268, indicating that the ability of
Gluint to protonate Gluext regulates transport probability in ClC-5
(Grieschat and Alekov, 2012).
The cytoplasmic domain of ClC-5 was found to bind
adenosine nucleotides in a site located between the CBS domains.
As binding of AMP, ADP or ATP occurs with similar affinities,
the physiological role of nucleotide binding remains unclear
(Meyer et al., 2007). Also, in the region between its two CBS
domains, ClC-5 carries a PY-motif known to bind WW-domains
of ubiquitin ligases (Schwake et al., 2001). Point mutations that
eliminate the PY-motif of ClC-5 double the currents and increase
cell surface localization upon heterologous expression (Schwake
et al., 2001). However, knock-in mice with a point mutation
disrupting the PY-motif lack any of the effects observed in vitro
(Rickheit et al., 2010).
ClC-5 and Dent’s Disease
Dent’s disease is a rare X-linked kidney disorder associated
with low molecular weight proteinuria, hyperphosphaturia,
hypercalciuria, kidney stones, and nephrocalcinosis (Wrong
et al., 1994). After the identification of ClC-5 mutations as the
cause of Dent’s disease (Lloyd et al., 1997), more than 100
such mutations were described (Pusch and Zifarelli, 2015). Most
mutations in ClC-5 are missense and non-sense mutations, with
many of them located at or near the subunit’s interface, resulting
in non-functional truncated proteins (Wu et al., 2003; Stauber
et al., 2012). Two missense mutations (G212A and E267A)
were analyzed regarding their functional consequences. The
particular interest in these mutations is explained by their close
proximity to Gluext (E211) and Gluint (E268). Both mutations
result in impaired endosomal acidification, however, the causes
are distinct. For the G212A mutant, a shift to more depolarizing
potentials is the cause of reduced transport, whereas in E267A
mutant the inability to transport intracellular protons results in
an incomplete transport cycle (Alekov, 2015).
Proximal tubule cells are the main site for re-uptake of low
molecular weight proteins from the primary urine filtrated at the
glomeruli. The co-localization of ClC-5 and H+-ATPase in PTCs,
and the loss of low molecular weight proteins in Dent’s disease
patients, suggests that ClC-5 might be involved in early tubular
endocytosis in nephrons. To better investigate this hypothesis,
two ClC-5 KO mice models were independently generated. Both
models showed loss of low molecular weight proteins and high
levels of retinal- and Vitamin D-binding proteins in the urine—
proteins also elevated in the urine of Dent’s disease patients
(Wrong et al., 1994), and defective endocytosis in the proximal
tubule (Piwon et al., 2000; Wang et al., 2000). Interestingly, only
one of the mouse models displayed hypercalciuria and interstitial
calcium accumulation (Wang et al., 2000). In vivo endocytosis
experiments showed that both fluid-phase and receptor-mediated
endocytosis were severely reduced, and that the apical expression
of NHE3 (Na+-H+ exchanger) and NaPi-2a (coupled Na+-Pi co-
transporter) were also reduced, all in a cell-autonomous effect of
ClC-5 disruption (Piwon et al., 2000).
Moreover, the protein megalin—an endocytotic receptor
responsible for the endocytosis of several proteins and other
substances—and its co-receptor cubilin were also decreased in
the brush border membrane of PTCs from ClC-5 KO mice
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FIGURE 5 | Proposed localization of intracellular CLC exchangers to the endosomal/lysosomal pathway. ClC-5 localizes to earlier compartments of the
pathway; ClC-3 and ClC-6 localize to later endosome compartments; ClC-7/Ostm1 localizes to lysosomes, the most acidic compartment. ClC-4 localization is still
unclear. The ATP-proton pump (pink) acidifies the compartments, increasing protons concentration down the pathway. ClC exchangers (green) provide the shunt
current in early endosomal compartments and accumulate chloride in lysosomes.
(Piwon et al., 2000; Christensen et al., 2003). Although almost all
Dent’s disease patients present low molecular weight proteinuria,
with values ranging from 100- to over 1000-fold of the normal
excretion values, the other clinical features show great variability
(Scheinman, 1998; Claverie-Martín et al., 2011).
Role of ClC-5 in low weight proteinuria, hyperphosphaturia,
and hypercalciuria
Luminal acidification is necessary for proper endosome function
(Clague et al., 1994) and ClC-5 was thought to provide the
electrical shunt necessary for the acidification of endosomes by
proton pumps (Piwon et al., 2000). Cl− ions transported by ClC-
5 provide the negative charge necessary for neutralization of
protons accumulating at the lumen of endosomes by the proton
pump (the electrical shunt), thus maintaining the acidification
process (Hara-Chikuma et al., 2005a). Indeed, ATP-induced
acidification in endosomes from ClC-5 KO animals was reduced
compared to wild-type animals (Günther et al., 2003; Novarino
et al., 2010). Furthermore, endocytosis experiments with cultured
PTCs using fluorescent-tagged markers for early/recycling and
late endosomes showed a reduction in both acidification and
Cl− accumulation in early, but not in late, endosomes (Hara-
Chikuma et al., 2005a). A defect in endocytosis was also observed
in cultured PTCs from ClC-5 KO mice (Wang et al., 2005).
Processes underlying the other symptoms of Dent’s disease—
such as hyperphosphaturia, hypercalciuria, and kidney
stones—are more complex. Reduced megalin expression at
the brush border membrane of PTCs due to ClC-5 disruption
impairs the endocytosis of PTH. Accumulation of PTH at the
renal tubules stimulates PTH receptors, which in turn results
in degradation and internalization of NaPi-2a transporters,
causing a reduction of phosphate re-absorption. Therefore,
hypophosphatemia/hyperphosphaturia is observed in both
Dent’s disease patients (Claverie-Martín et al., 2011) and ClC-5
KO mice (Piwon et al., 2000). About 30% of Dent’s disease
patients display hypophosphatemia due to loss of phosphate in
the urine (Claverie-Martín et al., 2011).
Proximal tubule cells are also the main site for vitamin D
metabolism, which plays a critical role in Ca2+ homeostasis. In
these cells, the inactive precursor 25(OH)-VitD3 is converted to
the active form 1,25(OH)2-VitD3 by the mitochondrial enzyme
1α-hydroxylase, which is stimulated by PTH (Murayama et al.,
1999). Megalin mediates the endocytosis of both active and
inactive forms of Vitamin D. Thus, in ClC-5 KO mice, whose
lack of ClC-5 results in low megalin expression in the brush
border of PTCs and impaired endocytosis, two stimuli may
upregulate 1α-hydroxylase expression: (1) overstimulation of
PTH receptors, and (2) decreased endocytosis of the active form
1,25(OH)2-VitD3, as this form represses enzyme transcription
(Murayama et al., 1999; Piwon et al., 2000; Günther et al., 2003;
Maritzen et al., 2006). Meanwhile, reduced endocytosis of the
inactive form 25(OH)-VitD3 is also in place, which would cause
downregulation of 1α-hydroxylase expression.
As regulation of 1,25(OH)2-VitD3 levels is governed by these
two opposing mechanisms, it was hypothesized that the balance
between precursor levels and those of its converting enzyme will
determine the presence—or not—of hypercalciuria (Figure 6).
If higher levels of 1α-hydroxylase lead to higher levels of
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1,25(OH)2-VitD3 in the serum, more calcium will be absorbed
in the intestine; therefore, more calcium will be excreted in
the urine, resulting in hypercalciuria and kidney stones. Indeed,
patients with Dent’s disease display a high prevalence (∼90%) of
hypercalciuria (Claverie-Martín et al., 2011), as well as elevated
levels of 1,25(OH)2-VitD3 (Scheinman, 1998).
Moreover, ClC-5 KO mouse models from Wang et al.
(2000) presenting hypercalciuria and renal calcium deposits
also displayed high levels of serum 1,25(OH)2-VitD3 (Wang
et al., 2000). In contrast, Piwon et al. (2000) did not identify
hypercalciuria in their ClC-5 KO mice, which displayed reduced
levels of serum 1,25(OH)2-VitD3 (Piwon et al., 2000; Maritzen
et al., 2006). There is a lack of reports associating hypercalciuria
and calcium deposits with serum levels of Vitamin D. Prospective
studies in large cohorts would be a valuable tool in the search for
pathophysiological mechanisms underlying Dent’s disease. Dent’s
disease is an excellent example of how a primary defect (impaired
endocytosis) in a restricted group of cells (PTCs) can lead to
a cascade of serious secondary complications (phosphaturia,
calciuria, kidney stones, and nephrocalcinosis).
ClC-5 As a Cl−/H+ Exchanger: New Insights on Its
Role in Endosomes
ClC proteins are involved in the acidification of both early
and late endosomes. Endosomal acidification is a process
mediated by active proton influx carried by the H+-ATPase.
The inward H+ movement requires a charge balance, which
can be achieved both by outward movement of cations such
as K+, and by inward movement of anions such as Cl−.
Extensive experimental data suggest that Cl− is the principal
ion providing the electrical shunt for luminal acidification of
endosomes (Bae and Verkman, 1990; Al-Awqati, 1995; Grabe
and Oster, 2001). After ClC-5 was determined to be a Cl−/H+
exchanger and not a Cl− channel (Picollo and Pusch, 2005;
Scheel et al., 2005), its role as an electrical shunt for proton
pumps was questioned; such an exchanger would provide a
counter-current of H+, opposing the ATP-driving accumulation
of protons.
To assess the consequences of this new CIC-5 feature, knock-
in mice were generated carrying a point mutation in the ‘gating
glutamate’ (E211A) that uncouples Cl− and H+ transport,
converting ClC-5 to a pure passive Cl− conductor (called ClC-
5unc; for uncoupled) (Novarino et al., 2010). Surprisingly, these
mice presented normal renal endosomal acidification, but also an
impaired proximal tubular endocytosis similar to that found in
ClC-5 KO mice. Two facts suggest that other parameters such as
Cl− concentration may play a critical role in endocytosis. First,
ClC-5unc mice presented phenotypes similar to the ClC-5 KO
group, including hypercalciuria and hyperphosphaturia. Second,
PTC endosomes from ClC-5unc showed normal acidification but
impaired endocytosis. Recently, a patient with Dent’s disease
was identified as carrying a similar mutation in the ‘gating
glutamate’ (E211Q) (Sekine et al., 2014). Further support for
the role of Cl− concentration in endocytosis comes from
mathematical models of simplified vesicles (containing a proton
pump, a proton leak and either a Cl−/H+ exchanger or a Cl−
channel) predicting that coupled transport would provide a
FIGURE 6 | Simplified model of the effect of impaired endocytosis due
to ClC-5 dysfunction in proximal tubular cells. In the early proximal
tubule, PTH and vitamin D3 (both precursor and active molecules) are filtered
into the primary urine. Those molecules are generally reabsorbed by
megalin-mediated endocytosis and subsequently degraded in lysosomes. The
megalin-mediated pathway is severely impaired in ClC-5 dysfunction. Under
normal conditions 25(OH)-vitamin D3 is metabolized by the mitochondrial
enzyme 1α-hydroxylase to the active hormone 1,25(OH)2-vitaminD3. In the
late proximal tubules, accumulation of PTH (due to impaired
megalin-mediated endocytosis) overstimulates PTH receptors, which
stimulate internalization and degradation of NaPi-2a transporters (green plus),
reducing phosphate re-absorption—hyperphosphaturia. Overstimulated PTH
receptors also upregulate the transcription of the mitochondrial enzyme
1α-hydroxylase (green plus). As megalin-dependent 25(OH)-vitaminD3
endocytosis is impaired, low levels of the precursor vitamin D have access to
its converting enzyme. Therefore, the delicate balance between the regulation
of 1α-hydroxylase transcription (that cooperates to increase active vitamin D3
levels) and the loss of the precursor form of vitamin D3 into the urine
(preventing its access to the enzyme), determine the outcome of either
increased or decreased concentration of active vitamin D3 in serum. Because
vitamin D3 levels drives the absorption of calcium to the bloodstream,
hypercalciuria and kidney stones may or may not develop.
higher endosomal Cl− concentration than a pure Cl− current
(Weinert et al., 2010). Unfortunately, the exact role of ClC-5
coupled Cl−/H+ transport in early endosomes is still not fully
understood.
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ClC-7: A lysosomal ClC Exchanger That
Requires a β-Subunit
ClC-7 is another broadly expressed ClC protein. In mouse
embryos, ClC-7 was found most prominently expressed in the
brain, eyes, spinal cord, and dorsal root and trigeminal ganglia in
mouse embryos (Kornak et al., 2001), whereas in adult mice it was
found in medulla oblongata, Purkinje cells, PTCs, Sertoli cells,
and pancreatic and tracheal epithelia (Kida et al., 2001). ClC-
7 localizes mostly in lysosomes (Figure 5) (Kornak et al., 2001;
Kasper et al., 2005; Poët et al., 2006; Wartosch et al., 2009), but is
also found in the ruﬄed border of osteoclasts (Kornak et al., 2001;
Lange et al., 2006). ClC-7 is the only ClC exchanger that requires
a β-subunit, Ostm1, for proper function. Ostm1 (osteopetrosis-
associated membrane protein 1), a highly glycosylated type 1
transmembrane protein, is essential for stability and transport
activity of ClC-7 (Lange et al., 2006; Leisle et al., 2011). Mutations
in the Ostm1 gene underlie the spontaneous gray-lethal mouse
mutant (Chalhoub et al., 2003). Ostm1 and ClC-7 co-localize in
lysosomes and in the ruﬄed border of osteoclasts and maintain
a closely dependent relationship, in which protein levels of one
are reduced by approximately 95% in the absence of the other
(Lange et al., 2006). Moreover, Ostm1 needs to interact with
ClC-7 in order to exit the ER and traffic to lysosomes, whereas
ClC-7 needs Ostm1 to be stable and functional (Lange et al.,
2006; Stauber and Jentsch, 2010). The transmembrane domain of
Ostm1 is necessary for ClC-7 trafficking to lysosomes, while the
highly glycosylated N-terminus plays a critical role in transport
activity of ClC-7 (Leisle et al., 2011).
For many years, the intracellular localization of CLC-7 has
hindered the study of its biophysical properties. However, after
the identification of a sorting motif localized at the cytosolic
N-terminus that directs ClC-7 to lysosomes (Stauber and Jentsch,
2010), point mutations that disrupt this motif allowed partial
cell-surface localization of ClC-7 upon heterologous expression,
allowing its biophysical characterization (Leisle et al., 2011). ClC-
7 shares several characteristics with other ClC exchangers such
as the strong outward rectification; anion sequence conductance
of Cl− > I−; inhibition of activity upon low extracellular pH;
and a classical 2Cl−/1H+ stoichiometry. However, activation
and deactivation of ClC-7 are very slow compared to other
ClC transporters, allowing for the analysis of tail currents. Tail
currents revealed that the exchange process is almost linearly
voltage-dependent, and rectification is almost entirely due to a
voltage gating (Leisle et al., 2011). Later, slow voltage-dependent
activation and deactivation of ClC-7 were assigned to the
common gating mechanism (Ludwig et al., 2013). ClC-7 also
carries both gating and proton glutamates; mutation of these
residues, such as is found in ClC-5, yields a protein displaying
a Cl− conductance uncoupled from H+ co-transport and a non-
functional ClC-7 protein, respectively (Kornak et al., 2001; Leisle
et al., 2011).
ClC-7 in Osteopetrosis, Retinal Degeneration, and
Lysosomal Storage Disease
To study the physiological roles of ClC-7/Ostm1, knock-
out mouse models were generated and analyzed. ClC-7 KO
mice present short life spans, severe osteopetrosis, retinal
degeneration, lysosomal storage disease, and neurodegeneration
(Kornak et al., 2001; Kasper et al., 2005). Gray-lethal mice (Ostm1
KO) display a very similar phenotype (Chalhoub et al., 2003;
Lange et al., 2006), as expected for these two closely functionally
related proteins. Interestingly, both ClC-7 KO and Ostm1 KO
mice have gray fur in an agouti background (in which wild-type
mice have brown fur), suggesting a possible role of ClC-7/Ostm1
in melanosomes (Kornak et al., 2001).
Loss of function of ClC-7 in osteoclasts results in
osteopetrosis, a disease characterized by increased bone
radiodensity because of ineffective osteoclast-mediated bone
resorption (Shapiro, 1993). The ruﬄed border of osteoclasts—a
membrane domain responsible for acidic digestion of bone
tissue—is formed by lysosomal membrane insertion and
exocytosis of their content. Acidification of the resorption
lacuna—the space between the ruﬄed border and the bone
tissue—is carried by V-type H+-ATPase that, similarly to
compartments of the endosomal/lysosomal pathway, requires
an electrical shunt thought to be performed by ClC-7/Ostm1
(Planells-Cases and Jentsch, 2009; Stauber et al., 2012). In the
resorption lacuna, ClC-7/Ostm1 is responsible for the Cl−
influx necessary for neutralization (shunting) of protons, which
keeps the proton pump functional and maintains the lacuna’s
highly acidic environment (Figure 7). Indeed, osteoclasts from
ClC-7 KO mice displayed underdeveloped ruﬄed borders and
impaired acidification of the resorption lacuna, which causes the
osteopetrotic phenotype (Kornak et al., 2001).
After establishment of the link between ClC-7/Ostm1
mutations and osteopetrosis, approximately 50 different human
ClC-7 mutations were identified in osteopetrotic patients (for
details, see Stauber et al., 2012). Most of these are missense
mutations, some of which cause an autosomal dominant form
of osteopetrosis that presents less severe symptoms and does
not implicate the nervous system (Cleiren et al., 2001; Frattini
et al., 2003). Others yield ClC-7/Ostm1 complexes, which are
retained in the ER or strongly reduce their ion transport activity
(Leisle et al., 2011). However, other missense mutations produce
transporters that reach the normal subcellular localization,
remaining functional when expressed heterologously in the
plasma membrane, and carrying the sorting motif point mutation
mentioned above. Curiously, these functional mutants yielded
currents with accelerated kinetics of activation and deactivation.
Given that patients carrying these mutations present symptoms
similar to others with non-functional transporters, the slow
gating of ClC-7/Ostm1 is likely physiologically important (Leisle
et al., 2011).
In addition to osteopetrosis, ClC-7 KO and gray-lethal mice
also display retinal and neurodegeneration associated with
lysosomal storage (Kornak et al., 2001; Kasper et al., 2005;
Lange et al., 2006). Retinal degeneration leads to blindness about
4 weeks after birth (Kornak et al., 2001; Lange et al., 2006).
Although previously the blindness was believed to be the result
of osteopetrotic narrowing of the optic nerve canal (Steward,
2003), retinal degeneration is a direct effect of disruption
of ClC-7 or Ostm1 at retinal neurons (Kasper et al., 2005).
Neurodegeneration is the probable cause of death of ClC-7
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FIGURE 7 | ClC-7 function at osteoclasts. Lysosomes are inserted into the ‘ruffled border’ of bone-attached osteoclasts. The resorption lacuna is then acidified
by the combined work of proton pumps (pink) and ClC-7/Ostm1 exchangers (green) present in the lysosomes membranes. Low pH conditions are required for the
chemical dissolution of inorganic bone material and for the activity of lysosomal enzymes that are secreted into the lacuna.
KO mice at approximately 6 weeks. They present neuronal
cell loss, particularly in the hippocampus and cerebral cortex,
as well as lysosomal storage material scattered throughout
the neuronal somata (Kasper et al., 2005). Neurodegeneration
and lysosomal storage disease are cell-autonomous effects of
disruption of ClC-7 as demonstrated by tissue-specific ClC-7 KO
mice. In this study, PTCs and neurons lacking or expressing
ClC-7 were compared within the same environment; only cells
devoid of ClC-7 displayed lysosomal disease (Wartosch et al.,
2009).
New Insights on the Role of C1C-7 in Lysosomes
In correlation with ClC-7 function in osteoclasts and ClC-3 to
ClC-5 roles in acidification of their respective compartments
(Mohammad-Panah et al., 2003; Hara-Chikuma et al., 2005a,b),
the lysosomal storage phenotype was first proposed to result
from impaired acidification. However, ratiometric measurements
showed that ClC-7/Ostm1 does not play a role in lysosomal
acidification; that is, lysosomes from ClC-7 KO mice display
normal steady-state pH (Kasper et al., 2005; Lange et al.,
2006; Weinert et al., 2010). The counter-charge conductance
suggested to neutralize H+-ATPase currents in this case seems
to be provided by a lysosomal cation eﬄux (Steinberg et al.,
2010).
These intriguing results concerning the function of ClC-7
in lysosomes led to the generation of two other ClC-7 mice
models, the ClC-7unc mice (Weinert et al., 2010)—generated
similarly to the ClC-5unc mice, by a ‘gating glutamate’ mutation
that yields uncoupled Cl− pure conductance—and the ClC-
7td mice (Weinert et al., 2014), generated by a mutation in
the ‘proton glutamate’ that abolishes transport (td: transport
deficient). Much like ClC-7 KO mice, both new models
displayed normal lysosomal pH and reduced Cl− concentration.
However, although ClC-7unc mice presented neuronal cell loss
and lysosomal storage disease similar to the ClC-KO mice, the
osteopetrotic phenotype was partially rescued by the presence
of pure Cl− currents (Weinert et al., 2010). Meanwhile, ClC-
7td mice displayed similar osteopetrotic phenotype to ClC-7 KO
mice, but a delayed and less severe neurodegeneration (Weinert
et al., 2014).
Surprisingly, unlike ClC-7 KO and Ostm1 KO mice, the
two new models presented normal agouti brown fur color
(Weinert et al., 2014). Taken together, these results suggest
that the physical presence of the non-functioning ClC-7td alone
was sufficient to rescue the normal fur pigmentation and
alleviate neurodegeneration, whereas ClC-7unc Cl− currents had
a positive effect in partially rescued osteopetrosis and normal
fur pigmentation, but a negative effect in neurodegeneration
(Weinert et al., 2014). Therefore, normal fur pigmentation seems
to require only the presence of ClC-7/Ostm1 complex, whereas
lysosomes and osteoclasts require fully functional Cl−/H+
exchangers in order to function properly. The precise role
of ClC-7 in lysosomes is still obscure, as is the previously
discussed role of ClC-5 in endosomes. More work is necessary
to better understand the role of coupled Cl−/H+ transport in the
endosomal/lysosomal pathway.
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ClCs with Uncertain Physiological
Function
The last sections of this review focuses on ClC-3, -4, and -6, which
have uncertain physiological functions. Although mutations or
dysfunction of these ClCs have not been linked directly to specific
human diseases, mouse models have demonstrated important
phenotypes that are worth discussing here.
ClC-3: Retinal and Brain Degeneration?
ClC-3 is a broadly expressed intracellular ClC protein with
controversial biophysical and physiological characteristics.
Several mutually conflicting Cl− currents have been attributed
to ClC-3. First, a slightly outwardly rectifying Cl− current
inhibited by PKC (Kawasaki et al., 1994); second, Cl− currents
inhibited by intracellular Ca+2 (Kawasaki et al., 1995), followed
by swelling-activated Cl− currents, also known as VRACs
(Duan et al., 1997). The role of VRACs was not confirmed
by data from three independently generated ClC-3 KO mice
(Stobrawa et al., 2001; Dickerson et al., 2002; Yoshikawa et al.,
2002), as swelling-activated Cl− currents were unaffected
in the hepatocytes, salivary acinar cells and cardiomyocytes
(Arreola et al., 2002; Gong et al., 2004). Moreover, a recent
report identified LRRC8 proteins as essential components of
VRACs, as their disruption abolishes VRAC currents (Voss et al.,
2014).
ClC-3 presents very low cell surface expression, even when
heterologously overexpressed, which has hindered a thorough
analysis of its biophysical properties. Nevertheless, in some
studies, small but strongly outwardly rectifying Cl− currents
were found (Li et al., 2002; Matsuda et al., 2008; Guzman et al.,
2013), similar to those reported for ClC-4 and ClC-5 (Steinmeyer
et al., 1995; Friedrich et al., 1999). Moreover, because of its
substantial sequence identity—approximately 80% with ClC-4
and ClC-5, which are well established ClC exchangers—and the
presence of the conserved ‘gating glutamate,’ which mutation
abolish rectification as in other ClCs, ClC-3 is most likely a
voltage dependent Cl−/H+ exchanger (Li et al., 2002; Guzman
et al., 2013).
ClC-3 is expressed in most tissues, including the brain, retina,
adrenal gland, pancreas, intestines, epididymis, kidney, liver,
skeletal muscle, and heart (Kawasaki et al., 1994; Stobrawa
et al., 2001; Suzuki et al., 2006; Maritzen et al., 2008). It mainly
resides in endosomes, where it was found co-localized with
ClC-4 and ClC-5, and also with both early and late endosomal
markers (Figure 5) (Suzuki et al., 2006). CLC-3 is also found in
synaptic vesicles (Stobrawa et al., 2001; Salazar et al., 2004) and
synaptic-like micro vesicles (Salazar et al., 2004; Maritzen et al.,
2008). Three different ClC-3 KO mouse lines displayed similar
phenotypes of severe degeneration of the retina and brain, with
prominent effects in the hippocampus (Stobrawa et al., 2001;
Dickerson et al., 2002; Yoshikawa et al., 2002). In one model, signs
of lysosomal storage disease were observed (Yoshikawa et al.,
2002), but these effects were much weaker than those found in
ClC-6 and ClC-7 KO mice (Poët et al., 2006; Kasper et al., 2005).
The mechanism by which ClC-3 causes neurodegeneration is still
unclear.
Although ClC-3 was thought to provide the electrical shunt
for acidification of intracellular compartments like the other
ClC exchangers, its role in endosomes and synaptic vesicles
is still controversial. In ClC-3 KO mice, acidification and Cl−
accumulation were reduced in early and late endosomes (Hara-
Chikuma et al., 2005b) and synaptic vesicles showed less efficient
acidification in vitro (Stobrawa et al., 2001). Synaptic vesicles
from ClC-3 KO mice exhibit reduced glutamate uptake, but
this feature has been ascribed to diminished levels of the
vesicular glutamate transporter VGLUT1 (Stobrawa et al., 2001).
In another study, evidence against ClC-3’s role in acidifying
synaptic vesicles was reported (Schenck et al., 2009). The fact that
VGLUT1 KO mice display no chloride-dependent acidification of
synaptic vesicles, and very little expression of CLC-3 in synapse
vesicles, led the authors to suggest that VGLUT1 represents the
major Cl− conductance pathway in synaptic vesicles (Schenck
et al., 2009). Therefore, the reduced acidification of synaptic
vesicle reported in ClC-3 KO mice (Stobrawa et al., 2001) was
attributed to reduced levels of VGLUT1, which itself most likely
resulted from severe neurodegeneration.
To avoid the effects of neurodegeneration on VGLUT1
levels, Guzman et al. (2014) used cultured hippocampal
neurons to analyze ClC-3 disruption in synaptic vesicles. The
authors observed enlargement of synaptic vesicles and increased
glutamate content in cells lacking ClC-3. The probability of
vesicle fusion and release of its content was also increased in
those cells, indicating that exaggerated release of glutamate in
the synaptic cleft contributes to neurodegeneration in ClC-3 KO
mice (Guzman et al., 2014).
Recently, reduced levels of ClC-3 were found in patients with
inflammatory bowel disease (IBD) and from mice treated with
dextran sulfate sodium (DSS) to induce colitis and mimic IBD.
ClC-3 KO mice were more susceptible to DSS-induced colitis
with no signs of recovery after treatment. Lack of ClC-3 provoked
apoptosis of intestinal epithelial cells, causing disruption of
the epithelial barrier and bacterial invasion. Thus, the authors
defend the involvement of ClC-3 in IBDs pathogenesis (Huang
et al., 2014). Another study points to ClC-3’s involvement
atherosclerosis. In an ApoE null mice background, further
disruption of ClC-3 reduced the size of atherosclerotic lesions
present in the aorta. The authors suggest that ClC-3 insufficiency
disrupts scavenger receptor SR-A expression (via JNK/p38
MAPK) and foam cell formation, leading to reduction/inhibition
of atherosclerotic lesions (Tao et al., 2015). The protective effect
of ClC-3 deficiency was again addressed in endothelial progenitor
cells (EPCs). Angiotensin II-induced apoptosis of EPCs was
remarkably reduced in ClC-3 KO mice. This inhibition was
attributed to suppressed levels of reactive oxygen species and
NADPH oxidase activity—direct effects of angiotensin-II—that
are suppressed by ClC-3 disruption (Liu et al., 2013).
Despite ClC-3 diversity in different cell types, phenotypes
present in ClC-3 KO mice strongly suggest that ClC-3 is
important for neurotransmission in the CNS. Three different
splicing variants of ClC-3 (ClC-3a, ClC-3b, and ClC-3c) were
described in the brain with different subcellular localization
but similar transport function (Guzman et al., 2015). Another
splicing variant, ClC-3d, was described in mouse livers
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as displaying different localizations but identical transport
properties (Okada et al., 2014). The number of splicing variants
with different subcellular localizations might explain the diversity
of functions ascribed to ClC-3; the study of these isoforms
could be a promising direction for further study of the precise
function and localization of ClC-3 proteins, which could provide
an explanation for the phenotypes described in KO mice.
ClC-4: A Cl−/H+ Exchanger with Unclear
Physiological Function
ClC-4 is a broadly expressed ClC exchanger found in various
tissues which differ between species. It is found mostly in the
muscles, brain, and heart of humans (van Slegtenhorst et al.,
1994); in the liver and brain, heart, muscles, spleen, and kidneys
of rats (Jentsch et al., 1995); and in the brain, intestines, and
kidneys of mice (Mohammad-Panah et al., 2003). Interestingly,
the gene encoding ClC-4 is localized on chromosome 7 in
inbred laboratory mice, but in humans and rats, the gene
resides on the X chromosome (Rugarli et al., 1995). This may
partially explain the variety and species-specificity of expression
patterns.
ClC-4 localizes mainly at endosomes’ membranes; upon
heterologous overexpression, a small portion is also found
within the plasma membrane (Mohammad-Panah et al., 2003;
Suzuki et al., 2006). Like other members of this family,
the cell surface localization allows for a better analysis of
its biophysical properties. ClC-4 yields a strongly outwardly
rectifying current that is inhibited by low extracellular pH;
to date, the physiological relevance of pH regulation remains
unclear. ClC-4 is a Cl−/H+ exchanger with anion conductance
sequence of Cl− > Br− > I−, similar to other intracellular ClCs.
Mutation of the ‘gating glutamate’ strongly changes rectification
and converts the exchanger into a passive Cl− conductor,
highlighting the importance of this residue in coupling proton
to Cl− transport (Friedrich et al., 1999; Picollo and Pusch, 2005;
Scheel et al., 2005).
Alekov and Fahlke (2009) have shown that ClC-4 proteins,
when exposed to different types of anions in the extracellular
buffer, can display a phenomenon called ‘slippage,’ where the
transporter behaves as a channel rather than an obligatory
exchanger. High extracellular SCN− cause increased current
amplitudes and uncouple H+ transport rendering ClC-4 channel-
like transport with reduced H+ currents and biophysical
properties similar to other well-characterized ClC channels.
Restoring extracellular Cl− rescues Cl−/H+ exchange. In ClC-
5, extracellular SCN− uncouples transport but does not affect
proton transport (Grieschat and Alekov, 2012), an apparent
isoform-specific effect. Thus, ClC-4 is suggested to function as
a channel or exchanger depending on the extracellular anion
(Alekov and Fahlke, 2009).
Currently, there is little scientific consensus regarding the sub-
cellular localization of ClC-4 (Figure 5). On those studies, ClC-4
was found in sub-apical vesicles of proximal tubule epithelium
(Mohammad-Panah et al., 2003); in intracellular compartments
of HEK 293 cells co-localizing with ClC-3 and ClC-5 (Suzuki
et al., 2006); and in the endoplasmic reticulum (Okkenhaug
et al., 2006). However, none of the immunohistochemistry studies
performed thus far have used cells from ClC-4 KO mice as a
negative control to confirm their data.
ClC-4 was suggested to facilitate endosomal acidification
by working as the electrical shunt for proton accumulation
mediated by the proton pump. However, ClC-4 KO mice do not
display any obvious abnormal phenotypes (Rickheit et al., 2010).
Although ClC-4 trafficking is similar to ClC-5, they do not appear
to perform similar physiological functions (Mohammad-Panah
et al., 2003). The additional disruption of ClC-4 in ClC-5 KO mice
did not aggravate the impaired endocytosis phenotype in PTCs
(Rickheit et al., 2010).
One naturally occurring mutation (G544R), found in a patient
with severe epilepsy and delayed development, nearly abolished
ClC-4 currents when expressed heterologously (Veeramah et al.,
2013). Hu et al. (2015), analyzing X-linked intellectual disabilities,
identified five different mutations in the ClC-4 gene in five
families. Currents of ClC-4 proteins carrying each of these
mutations were much smaller or even absent compared to wild-
type ClC-4. Moreover, C1C-4 depletion in cultured hippocampal
neurons, affected neuronal differentiation; the cells displayed
a 30% reduction of neuritic outgrowth and branching (Hu
et al., 2015). Additional studies using specific antibodies and
appropriate KO controls are necessary to further understand
ClC-4 physiological function in specific cell compartments,
determine precise sub-cellular localization, and investigate
possible roles in human diseases.
ClC-6: Mild Lysosomal Storage Disease?
ClC-6 shares approximately 45% of its sequence identity with
ClC-7; together, they form the third branch of the ClC protein
family. Like other ClC exchangers, ClC-6 localizes at membranes
of the endosomal/lysosomal pathway (Figure 5) (Poët et al.,
2006). ClC-6 mRNA was found in several tissues (Brandt and
Jentsch, 1995), but the expressed ClC-6 protein is found almost
exclusively in the nervous system (Poët et al., 2006). First attempts
to record ClC-6 currents by heterologous expression were
frustrated by its late endosomal localization (Brandt and Jentsch,
1995; Buyse et al., 1998), and biophysical characterization only
became possible when GFP-tagged ClC-6 proteins were expressed
in the plasma membrane (Neagoe et al., 2010). ClC-6 mediates
outwardly rectifying currents that are reduced by extracellular
acidification, as in other ClC-exchangers. Mutation in the ‘gating
glutamate’ also disrupts rectification, turning ClC-6 into a passive
Cl− conduit (Neagoe et al., 2010).
Knock-out controlled immunohistochemistry studies have
shown that native ClC-6 localizes predominantly at late
endosomes of neurons in situ (Poët et al., 2006) and in cultured
cells (Ignoul et al., 2007), whereas in heterologous expression it
is also found co-localized with early and late endosomal markers
(Suzuki et al., 2006; Stauber and Jentsch, 2010).
ClC-6 KO mice present no apparent abnormal phenotypes,
with normal life span and weight. However, late in life
(>3 months old), the mice display a peculiar form of lysosomal
storage disease, with deposits found in central and peripheral
neurons (Poët et al., 2006). Different from ClC-7 KO mice, in
which such deposits are localized all over the neuronal soma
and the disease progression is much more aggressive, deposits in
Frontiers in Pharmacology | www.frontiersin.org 18 March 2017 | Volume 8 | Article 151
fphar-08-00151 March 21, 2017 Time: 15:52 # 19
Poroca et al. ClC Channels in Human Channelopathies
ClC-6 KO neurons are mainly localized at initial axon segments
and the disease progresses very slowly (Poët et al., 2006; Pressey
et al., 2010). Moreover, the absence of ClC-6 in hippocampal
neurons does not affect lysosomal steady-state pH (Poët et al.,
2006). Deposits found in ClC-6 KO mice tested positive for
markers typically found in neuronal ceroid lipofuscinosis (NCL),
a lysosomal storage disease. The authors therefore proposed
ClC-6 gene as a candidate for mild forms of NCL, but did not find
convincing association upon analysis of 75 NCL patients (Poët
et al., 2006).
In general, neuropathology in ClC-6 KO mice is much
milder than in ClC-3 and ClC-7 KO mice. They show no
vision impairment, and little neuronal cell loss and microglial
activation (Poët et al., 2006; Pressey et al., 2010). ClC-6 KO
mice also demonstrate reduced pain sensitivity, correlated with
an impairment of dorsal root ganglion neuronal function due to
dramatic lysosomal storage accumulation (Poët et al., 2006). After
all, like ClC-3 and ClC-4, ClC-6 is another ClC exchanger whose
physiological role is poorly understood at present.
CONCLUSION
Cl− ion transport has risen from obscurity to become a vibrant
and exciting field in ion transport research. Within this field, ClC
proteins are a particularly intriguing family of anion channels
and transporters involved in several important physiological
functions. Twenty-five years after the discovery of its first
member (ClC-0), and following enormous efforts to study their
biological aspects, many questions about the structure, function,
and pathophysiological roles of ClCs have been answered, but
an equally high number of new and, so far, unsolved questions
have emerged. For instance, the precise localization of ClC-K
channels in the thin limb of the loop of Henle in the kidney and its
function in intercalated cells are still unknown. Future research
topics of particular interest include a better understanding of the
relationship between α- and β-subunits, and of the physiological
role of β-subunits by themselves.
Phenotypes of mouse models have linked ClC protein
function and dysfunction with inherited human genetic diseases.
Myotonia congenita, leukodystrophy, Bartter syndrome, Dent’s
disease, and osteopetrosis/retinal degeneration/lysosomal storage
disease have well-established association with loss-of-function
of ClC1, ClC-2, ClC-K/Barttin, ClC-5 and ClC-7/Ostm1,
respectively. However, many aspects of these diseases’ molecular
origins remain obscure.
Useful tools to increase our knowledge about the molecular
basis of ClC-related diseases would include the development of
small molecules able to specifically block or activate ClC proteins.
Unfortunately, currently available compounds targeting ClC
proteins are few and far between, and they lack specificity. The
role of intracellular ClC exchangers in the endosomal/lysosomal
pathway is not completely established. Acidification and Cl−
accumulation seem not to be the only functions of ClC
exchangers in these compartments. Interactions with other cell
proteins—and not only transport activity of ClC exchangers—
seem to play a role in endosome/lysosome homeostasis, as
revealed by the rescue of some pathological phenotypes in KO
mice upon the expression of non-functional ClC-7 proteins.
Some phenotypes displayed by ClC-3 and ClC-6 KO mice could
not be correlated with the physiological roles so far assigned to
ClC-3 and ClC-6. However, this may be only a matter of time;
recently, leukodystrophy and azoospermia—typically phenotypes
of ClC-2 KO mice—were described in patients with ClC-2
mutations.
Crystal structures of prokaryote and eukaryote ClC proteins
have provided important insights about molecular structure
and ion conductance mechanisms. ClC proteins are unique in
their double-barreled structure, providing a new model of ion
transport in which the same basic architecture supports bona
fide channel conductance and ion co-transport. These two types
of ion translocation were believed to occur by entirely distinct
mechanisms. However, the available crystal structures were not
sufficient to uncover the molecular mechanism governing the
common gating mechanism and the precise proton transport
pathway. Use of new approaches or the development of
novel techniques may be necessary to uncover the molecular
mechanisms underlying ClC ion transport.
Generation of crystal structures of mammalian ClC channels
and exchangers will ultimately permit a more accurate
investigation into the differences between these two structures,
and also the identification of regions involved in interaction
and modulation by other cellular components. Moreover,
those structures will greatly assist in the development of new
compounds able to modify specific types of ClC proteins,
thus opening the field for pharmacological approaches aiming
at generating therapeutic drugs. Such drugs would have the
potential to reduce or even eliminate the undesired symptoms
caused by ClC proteins loss-of-function, improving quality of life
for many patients.
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